Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.

Abstract

BACKGROUND:

Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders.

METHODS:

In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1.

RESULTS:

Five patients had genotype 1a and 10 patients had genotype 1b chronic hepatitis C. One patient had Child A cirrhosis, 14 patients had chronic hepatitis C without cirrhosis. Hepatitis C virus ribonucleic acid was negative in all patients at week 4 and at the end of the treatment. Sustained virologic response was obtained in all patients. Serious side effects were detected in 3 patients, which were intra- muscular bleeding, erosive gastritis-related gastrointestinal bleeding, and pneumonia.

CONCLUSION:

Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders. Tolerance and side effects are similar to other treatment options.

• Authors: Abdullah Sonsuz, Selma Bozcan, İbrahim Hatemi, Sebati Özdemir, Billur Canbakan, Süleyman Yıldırım, İlkay Gültürk, Cem Ar
• Journal: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology (Turk J Gastroenterol) Vol. 33 Issue 5 Pg. 414-420 (05 2022) ISSN: 2148-5607 [Electronic] Turkey
• PMID: 35678799 (Publication Type: Journal Article)

Chemical References

• Anilides
• Antiviral Agents
• Carbamates
• Cyclopropanes
• Lactams, Macrocyclic
• Macrocyclic Compounds
• Sulfonamides
• ombitasvir
• Ribavirin
• Uracil
• Proline
• 2-Naphthylamine
• dasabuvir
• Valine
• Ritonavir
• paritaprevir

Topics

• 2-Naphthylamine
• Adult
• Anilides (therapeutic use)
• Antiviral Agents (therapeutic use)
• Carbamates (therapeutic use)
• Child
• Cyclopropanes
• Drug Therapy, Combination
• Genotype
• Hepacivirus (genetics)
• Hepatitis C (drug therapy)
• Hepatitis C, Chronic
• Humans
• Lactams, Macrocyclic
• Liver Cirrhosis
• Macrocyclic Compounds (therapeutic use)
• Proline (analogs & derivatives)
• Retrospective Studies
• Ribavirin (therapeutic use)
• Ritonavir (therapeutic use)
• Sulfonamides
• Uracil (analogs & derivatives)
• Valine (therapeutic use)